301. 黄斑ジストロフィー Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
ACU-4429
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-IT Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
ALK-001
Alkeus Pharmaceuticals, Inc.
2019 Phase 2 NCT04239625 United States;
2015 Phase 2 NCT02402660 United States;
ALK-001 (No generic name)
Alkeus Pharmaceuticals, Inc.
2014 Phase 1 NCT02230228 -
ARC1905
IVERIC bio, Inc.
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
ARC1905 20 MG/ML
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Avacincaptad pegol
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
IVERIC bio, Inc.
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Docosahexaenoic Acid (DHA) Dietary Supplement
National Eye Institute (NEI)
2003 Phase 1 NCT00060749 United States;
EMIXUSTAT HYDROCHLORIDE (ACU-4429)
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-NL Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-GB Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-ES Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-DK Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-003498-82-FR Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-003498-82-DE Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
EU/3/13/1208 orphan
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
Emixustat
Kubota Vision Inc.
2018 Phase 3 NCT03772665 Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2017 Phase 2 NCT03033108 United States;
Emixustat hydrochloride
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-IT Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
HESC-RPE
Astellas Institute for Regenerative Medicine
2013 - NCT02941991 United Kingdom;
Interferon gamma-1b
National Eye Institute (NEI)
2015 Phase 1/Phase 2 NCT02338973 United States;
Lentiviral vector containing ABCA4 gene
Oxford BioMedica (UK) Ltd
2011 Phase 1;Phase 2 EUCTR2010-023111-34-FR France;Italy;Netherlands;
sanofi-aventis recherche et développement
2016 - EUCTR2010-023111-34-NL France;Italy;Netherlands;United States;
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Sanofi
2012 Phase 1/Phase 2 NCT01736592 France;United States;
MA09-hRPE
Astellas Institute for Regenerative Medicine
2012 - NCT02445612 United States;
2011 Phase 1/Phase 2 NCT01469832 United Kingdom;
2011 Phase 1/Phase 2 NCT01345006 United States;
CHABiotech CO., Ltd
2012 Phase 1 NCT01625559 Korea, Republic of;
Madeos
Ophthalmos Research and Education Institute
2019 - NCT03297515 France;Germany;Italy;
Metformin hydrochloride
National Eye Institute (NEI)
2020 Phase 1/Phase 2 NCT04545736 United States;
Over the counter DHA/EPA dietary supplementation
University of Utah
2007 - NCT00420602 United States;
Ranibizumab injection (0.5 mg)
Manhattan Eye, Ear & Throat Hospital
2007 Phase 1/Phase 2 NCT00470977 United States;
SAR422459
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2018 Phase 1;Phase 2 EUCTR2010-023111-34-IT France;Italy;Netherlands;United States;
Sanofi
2011 Phase 1/Phase 2 NCT01367444 France;United States;
sanofi-aventis recherche et développement
2016 - EUCTR2010-023111-34-NL France;Italy;Netherlands;United States;
STG-001
Stargazer Pharmaceuticals, Inc.
2020 Phase 2 NCT04489511 United States;
Saffron supplementation
Catholic University of the Sacred Heart
2011 Phase 1/Phase 2 NCT01278277 Italy;
Sildenafil
Columbia University
2014 Phase 2 NCT04356716 United States;
Soraprazan
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
StarGen
Oxford BioMedica (UK) Ltd
2011 Phase 1;Phase 2 EUCTR2010-023111-34-FR France;Italy;Netherlands;
Stem/progenitor cells transplantation
Pomeranian Medical University Szczecin
2018 Phase 1 NCT03772938 Poland;
Tinlarebant
Belite Bio, Inc
2022 Phase 3 NCT05244304 Australia;France;Germany;Hong Kong;Switzerland;Taiwan;United Kingdom;United States;
RBP4 Pty Ltd
2021 Phase 1/Phase 2 NCT05266014 Australia;Taiwan;
VA
Columbia University
2014 Phase 2 NCT04356716 United States;
Vett Lentiviral con gene ABCA4
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2018 Phase 1;Phase 2 EUCTR2010-023111-34-IT France;Italy;Netherlands;United States;
Zimura
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
IVERIC bio, Inc.
2018 Phase 2 NCT03364153 Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
ACU-4429
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-IT Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
ALK-001
Alkeus Pharmaceuticals, Inc.
2019 Phase 2 NCT04239625 United States;
2015 Phase 2 NCT02402660 United States;
ALK-001 (No generic name)
Alkeus Pharmaceuticals, Inc.
2014 Phase 1 NCT02230228 -
ARC1905
IVERIC bio, Inc.
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
ARC1905 20 MG/ML
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Avacincaptad pegol
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
IVERIC bio, Inc.
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
Docosahexaenoic Acid (DHA) Dietary Supplement
National Eye Institute (NEI)
2003 Phase 1 NCT00060749 United States;
EMIXUSTAT HYDROCHLORIDE (ACU-4429)
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-NL Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-GB Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-ES Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003498-82-DK Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-003498-82-FR Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
- Phase 3 EUCTR2018-003498-82-DE Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
EU/3/13/1208 orphan
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
Emixustat
Kubota Vision Inc.
2018 Phase 3 NCT03772665 Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
2017 Phase 2 NCT03033108 United States;
Emixustat hydrochloride
Acucela Inc.
2019 Phase 3 EUCTR2018-003498-82-IT Brazil;Canada;Denmark;France;Germany;Italy;Netherlands;South Africa;Spain;United Kingdom;United States;
HESC-RPE
Astellas Institute for Regenerative Medicine
2013 - NCT02941991 United Kingdom;
Interferon gamma-1b
National Eye Institute (NEI)
2015 Phase 1/Phase 2 NCT02338973 United States;
Lentiviral vector containing ABCA4 gene
Oxford BioMedica (UK) Ltd
2011 Phase 1;Phase 2 EUCTR2010-023111-34-FR France;Italy;Netherlands;
sanofi-aventis recherche et développement
2016 - EUCTR2010-023111-34-NL France;Italy;Netherlands;United States;
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Sanofi
2012 Phase 1/Phase 2 NCT01736592 France;United States;
MA09-hRPE
Astellas Institute for Regenerative Medicine
2012 - NCT02445612 United States;
2011 Phase 1/Phase 2 NCT01469832 United Kingdom;
2011 Phase 1/Phase 2 NCT01345006 United States;
CHABiotech CO., Ltd
2012 Phase 1 NCT01625559 Korea, Republic of;
Madeos
Ophthalmos Research and Education Institute
2019 - NCT03297515 France;Germany;Italy;
Metformin hydrochloride
National Eye Institute (NEI)
2020 Phase 1/Phase 2 NCT04545736 United States;
Over the counter DHA/EPA dietary supplementation
University of Utah
2007 - NCT00420602 United States;
Ranibizumab injection (0.5 mg)
Manhattan Eye, Ear & Throat Hospital
2007 Phase 1/Phase 2 NCT00470977 United States;
SAR422459
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2018 Phase 1;Phase 2 EUCTR2010-023111-34-IT France;Italy;Netherlands;United States;
Sanofi
2011 Phase 1/Phase 2 NCT01367444 France;United States;
sanofi-aventis recherche et développement
2016 - EUCTR2010-023111-34-NL France;Italy;Netherlands;United States;
STG-001
Stargazer Pharmaceuticals, Inc.
2020 Phase 2 NCT04489511 United States;
Saffron supplementation
Catholic University of the Sacred Heart
2011 Phase 1/Phase 2 NCT01278277 Italy;
Sildenafil
Columbia University
2014 Phase 2 NCT04356716 United States;
Soraprazan
Katairo GmbH
2019 Phase 2 EUCTR2018-001496-20-IT Germany;Italy;Netherlands;United Kingdom;
StarGen
Oxford BioMedica (UK) Ltd
2011 Phase 1;Phase 2 EUCTR2010-023111-34-FR France;Italy;Netherlands;
Stem/progenitor cells transplantation
Pomeranian Medical University Szczecin
2018 Phase 1 NCT03772938 Poland;
Tinlarebant
Belite Bio, Inc
2022 Phase 3 NCT05244304 Australia;France;Germany;Hong Kong;Switzerland;Taiwan;United Kingdom;United States;
RBP4 Pty Ltd
2021 Phase 1/Phase 2 NCT05266014 Australia;Taiwan;
VA
Columbia University
2014 Phase 2 NCT04356716 United States;
Vett Lentiviral con gene ABCA4
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2018 Phase 1;Phase 2 EUCTR2010-023111-34-IT France;Italy;Netherlands;United States;
Zimura
IVERIC bio
2018 Phase 2 EUCTR2017-004783-35-HU Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-GB Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-DE Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
IVERIC bio, Inc.
2018 Phase 2 NCT03364153 Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2017-004783-35-IT Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;
OPHTHOTECH CORPORATION
2018 Phase 2 EUCTR2017-004783-35-ES Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States;